Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2013		Jul. 01, 2012		Jun. 30, 2013		Jul. 01, 2012
Revenue from External Customer [Line Items]
Gains (Losses) on Sales of Assets	$ (31)	[1]	$ 0	[1]	$ 459	[1]	$ 0	[1]
Revenues	12,973		13,968		25,383		27,813
Biopharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	12,110		13,139		23,656		26,204
Biopharmaceutical [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	1,134		1,035		2,200		1,990
Biopharmaceutical [Member] | Prevnar/ Prevenar family [Member]
Revenue from External Customer [Line Items]
Revenues	969		996		1,896		2,079
Biopharmaceutical [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues	960		988		1,837		1,887
Biopharmaceutical [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	715		659		1,368		1,293
Biopharmaceutical [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	545	[2]	1,220	[2]	1,171	[2]	2,615	[2]
Biopharmaceutical [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	484		485		945		981
Biopharmaceutical [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	346		343		688		668
Biopharmaceutical [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues	312		319		614		619
Biopharmaceutical [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	313		348		614		682
Biopharmaceutical [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues	273		274		517		535
Biopharmaceutical [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues	198		212		387		407
Biopharmaceutical [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues	217		193		406		376
Biopharmaceutical [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	177		178		364		356
Biopharmaceutical [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues	166		172		332		350
Biopharmaceutical [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues	177		158		343		309
Biopharmaceutical [Member] | Detrol / Detrol LA [Member]
Revenue from External Customer [Line Items]
Revenues	155		205		306		400
Biopharmaceutical [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	147		209		294		436
Biopharmaceutical [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues	146		138		285		270
Biopharmaceutical [Member] | Zithromax / Zmax [Member]
Revenue from External Customer [Line Items]
Revenues	83		106		199		229
Biopharmaceutical [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	109		139		225		269
Biopharmaceutical [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	123		141		236		275
Biopharmaceutical [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	125		106		230		235
Biopharmaceutical [Member] | Zosyn / Tazocin [Member]
Revenue from External Customer [Line Items]
Revenues	102		141		189		269
Biopharmaceutical [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues	92		86		179		167
Biopharmaceutical [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues	94		89		180		174
Biopharmaceutical [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	94		101		180		192
Biopharmaceutical [Member] | Rapamune [Member]
Revenue from External Customer [Line Items]
Revenues	86		85		170		167
Biopharmaceutical [Member] | Cardura [Member]
Revenue from External Customer [Line Items]
Revenues	75		91		151		175
Biopharmaceutical [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	73		92		145		150
Biopharmaceutical [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues	78		143		150		279
Biopharmaceutical [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	73		71		144		129
Biopharmaceutical [Member] | Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues	65		69		135		137
Biopharmaceutical [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues	71		17		134		24
Biopharmaceutical [Member] | Aricept [Member]
Revenue from External Customer [Line Items]
Revenues	59	[3]	84	[3]	121	[3]	178	[3]
Biopharmaceutical [Member] | Unasyn [Member]
Revenue from External Customer [Line Items]
Revenues	53		57		109		111
Biopharmaceutical [Member] | Caduet [Member]
Revenue from External Customer [Line Items]
Revenues	56		58		112		123
Biopharmaceutical [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues	66		67		111		134
Biopharmaceutical [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues	67		23		120		40
Biopharmaceutical [Member] | Neurontin [Member]
Revenue from External Customer [Line Items]
Revenues	56		62		108		120
Biopharmaceutical [Member] | Diflucan [Member]
Revenue from External Customer [Line Items]
Revenues	60		67		105		124
Biopharmaceutical [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues	55		49		103		94
Biopharmaceutical [Member] | Metaxalone Skelaxin [Member]
Revenue from External Customer [Line Items]
Revenues	66		61		96		94
Biopharmaceutical [Member] | Depo-Provera [Member]
Revenue from External Customer [Line Items]
Revenues	54		44		90		77
Biopharmaceutical [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues	22		0		33		0
Biopharmaceutical [Member] | Inspra [Member]
Revenue from External Customer [Line Items]
Revenues	59		56		111		105
Biopharmaceutical [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	65		52		117		98
Biopharmaceutical [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues	756	[4]	862	[4]	1,503	[4]	1,698	[4]
Biopharmaceutical [Member] | All Other Biopharmaceutical Products [Member]
Revenue from External Customer [Line Items]
Revenues	1,839		1,988		3,603		4,084
Other products [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	800		769		1,611		1,496
Other products [Member] | Pfizer Centre Source And Other [Member]
Revenue from External Customer [Line Items]
Revenues	$ 63	[5]	$ 60	[5]	$ 116	[5]	$ 113	[5]

[1] In the first six months of 2013, represents the gain associated with the transfer of certain product rights to our equity-method investment in China. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.

[2] Lipitor lost exclusivity in the U.S. in November 2011 and various other major markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenues by $657 million in the second quarter of 2013, in comparison with the second quarter of 2012, and by $1.4 billion in the first six months of 2013, in comparison with the first six months of 2012.

[3] Represents direct sales under license agreement with Eisai Co., Ltd.

[4] Includes Enbrel (in the U.S. and Canada), Spiriva, Rebif, Aricept and Eliquis.

[5] Represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization.